目的 探讨肝衰竭患者应用双重血浆分子吸附系统联合血浆置换治疗期间采用不同封管方法的效果比较。 方法 选择2022年1月至2024年10月收治的肝衰竭者120例，分为观察组和对照组各60例。两组均实施双重血浆分子吸附系统联合血浆置换的治疗方法，对照组患者应用肝素钠封管，观察组在肝素钠封管前加用鱼精蛋白。比较两组在肝功能相关指标［天门冬氨酸氨基转移酶（aspartate transaminase， AST）、丙氨酸氨基转移酶（alanine transaminase， ALT）、胆红素］、止凝血功能相关指标［纤维蛋白原、国际标准化比值（international normalized ratio，INR）］、血常规相关指标［血红蛋白（hemoglobin，Hb）］、堵管率与不良反应发生率上的差异。 结果 两组患者治疗后肝功能相关指标、止凝血功能相关指标、血常规相关指标组间比较，差异无统计学意义（P > 0.05）；观察组患者堵管率（3.33%）低于对照组堵管率（20.00%），差异有统计学意义（P < 0.05）；两组患者发生不良反应率比较，差异无统计学意义（P > 0.05）。 结论 双重血浆分子吸附系统联合血浆置换治疗肝衰竭的过程，在肝素钠封管前使用鱼精蛋白对患者肝功能、血常规、止凝血功能及不良反应发生的影响小，但可以降低堵管率。

Objective To explore the effects of different sealing methods in the treatment of liver failure patients using a dual plasma molecular adsorption system combined with plasma exchange. Methods A total of 120 patients with liver failure admitted between January 2022 and October 2024 were enrolled in the study and randomly divided into an observation group and a control group， each consisting of 60 patients. Both groups received treatment with a dual plasma molecular adsorption system combined with plasma exchange. The control group was administered heparin sodium for catheter sealing， whereas the observation group received protamine prior to heparin sodium catheter sealing. The study compared the two groups in terms of liver function indicators—including aspartate aminotransferase （AST）， alanine aminotransferase （ALT）， and bilirubin—coagulation function indicators such as fibrinogen and international normalized ratio （INR）， hemoglobin （HGB） levels， catheter blockage rates， and the incidence of adverse reactions. Results No statistically significant differences were observed in liver function， coagulation function， or routine blood parameters between the two patient groups following treatment （P > 0.05）. However， the incidence of blockage in the observation group （3.33%） was significantly lower than that in the control group （20.00%）， with the difference being statistically significant （P < 0.05）. Additionally， no significant differences were found in the occurrence of adverse reactions between the two groups （P > 0.05）. Conclusions The treatment of liver failure involves the use of a dual plasma molecular adsorption system combined with plasma exchange. Administering protamine prior to heparin sodium sealing has minimal impact on the patient's liver function， blood parameters， coagulation profile， and incidence of adverse reactions， yet it effectively reduces the risk of circuit clotting.